Skip to main content
EnglishEN
European Commission logo print header

Training Network for the education of the next generation scientist in targeting the supressive capacity of regulatory T-cells specifically within tumours

Objective

Tumour immune-therapy has made dramatic improvements in recent years, saving the lives of cancer patients who just a
few years ago would have been considered untreatable. It thereby became apparent that one specific type of immune cell,
so called regulatory T-cells, critically hampers the efficacy of tumour immune-therapy. Tumours, however, attract and exploit
the immune-regulatory function of Tregs to dampen local immune responses and to induce local tolerance.
In recent years, inhibitors that directly target immune-suppressive mechanisms of T cells have found clinical application with
great success. The clinical application of these so called “check-point inhibitors”, however, is accompanied by severe side
effects in treated patients. Thus improvement of the efficacy of current immune-therapeutic treatments is a major unmet
need. This proposal will employ the newest developments in antibody design to target the next generation of biologics right
towards tumour-residential Tregs or directly into the tumour micro-environment itself. In this way we will be able to
specifically shift the local immune suppressive environment within tumours, while leaving tissue homeostasis in noncancerous
tissues unaffected, and thus diminish treatment associated side-effects.
The here proposed project combines the expertise of fundamental immunologist, tumour immunologists and cell biologists
with that of a life-science biotechnology company and that of experts in clinical cancer research to address this aspect. This
group will lead a training network that aims at educating a new generation of researchers, who will be able to bridge the
innovation gap between, on the one hand, early discoveries in tumour-immunology as well as in antibody technology and, on
the other hand, the efficient translation and clinical validations of these findings in patients.

Fields of science

Programme(s)

Topic(s)

Call for proposal

H2020-MSCA-ITN-2017

See other projects for this call

Funding Scheme

MSCA-ITN-EID - European Industrial Doctorates

Coordinator

UNIVERSIDAD DE NAVARRA
Net EU contribution
€ 247 872,96
Address
Campus universitario edificio central
31080 Pamplona
Spain

See on map
Region
Noreste Comunidad Foral de Navarra Navarra
Activity type
Higher or Secondary Education Establishments
Links
Other funding
€ 0,00

Participants (5)

Partners (2)

Share this page

Download

EC signature date 2 August 2017
Last update: 27 September 2022

My Booklet

Permalink: https://cordis.europa.eu/project/id/765394

European Union, 2023